HPMA copolymer-1,5-diazaanthraquinone conjugates as novel anticancer therapeutics.
1,5-diazaanthraquinones (DAQs) are promising anticancer drugs, however, their clinical potential is limited due to poor solubility. Conjugation of anticancer agents to hydrophilic water-soluble polymers can overcome this problem and has already been used to generate conjugates with demonstrated clinical benefit. Here a library of N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer conjugates containing a novel amino-functionalised 1,5-diazaanthraquinone derivative (amino-DAQ) have been synthesised. The conjugates were fully characterised by UV, HPLC, SEC, FT-Raman and NMR spectroscopy. Conjugation to HPMA copolymers improved amino-DAQ aqueous solubility (>7-fold). The HPMA copolymer-amino-DAQ conjugates were slightly less haemolytic than the parent compound (2% Hb released in 1 h for conjugate HPMA copolymer-GFLG (5 mol%)-amino-DAQ conjugate compared to 13% obtained with amino-DAQ). When conjugates were incubated with isolated rat liver lysosomal enzymes (Tritosomes) the rate of amino-DAQ release was influenced by both drug loading and the composition of the peptidyl side chain used to link the drug to the carrier. The higher the drug loading the lower the rate of drug release. Whereas the GG linker did not release amino-DAQ, up to 26% of the amino-DAQ was released from a GFLG linker over 24 h. The in vitro cytotoxicity of these conjugates was evaluated against two different cell lines, B16F10 murine melanoma and MCF-7 human breast cancer cells. HPMA copolymer-amino-DAQ conjugates, which are internalised by cells by the endocytic pathway, showed much lower in vitro cytotoxicity (IC50 for HPMA copolymer-GFLG (5 mol%)-amino-DAQ conjugate>397 microM drug-equiv.) than the free drug (the IC50 for amino-DAQ was 12.6 and 2.8 microM against the B16F10 murine melanoma and the MCF-7 breast cancer cell line, respectively). Nonetheless, the observed lysosomal activation of the HPMA copolymer-GFLG-amino-DAQ conjugates, suggests that evaluation of the antitumour potential in vivo is warranted.
Vicent
María J
MJ
Centre for Polymer Therapeutics, Welsh School of Pharmacy, Cardiff University, Cardiff, UK. mjvicent@ochoa.fib.es
Manzanaro
Sonia
S
de la Fuente
Jesús A
JA
Duncan
Ruth
R
D000818:Animals; D000880:Anthraquinones / Q000032:analysis / Q000737:chemistry* / Q000494:pharmacology; D000970:Antineoplastic Agents / Q000032:analysis / Q000737:chemistry* / Q000494:pharmacology; D045744:Cell Line, Tumor; D002470:Cell Survival / Q000187:drug effects / Q000502:physiology; D016503:Drug Delivery Systems / Q000379:methods; D008546:Melanoma, Experimental; D008689:Methacrylates / Q000032:analysis / Q000737:chemistry* / Q000494:pharmacology; D051379:Mice; D011108:Polymers / Q000032:analysis / Q000737:chemistry* / Q000494:pharmacology; D051381:Rats
D000880:Anthraquinones; D000970:Antineoplastic Agents; D008689:Methacrylates; D011108:Polymers; C032802:hydroxypropyl methacrylate